Pro- and Antitumorigenic Capacity of Immunoproteasomes in Shaping the Tumor Microenvironment
Open Access
- 11 March 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (6) , 682-692
Abstract
Apart from the constitutive proteasome, the immunoproteasome that comprises the three proteolytic subunits LMP2, MECL-1, and LMP7 is expressed in most immune cells. In this study, we describe opposing roles for immunoproteasomes in regulating the tumor microenvironment (TME). During chronic inflammation, immunoproteasomes modulated the expression of protumorigenic cytokines and chemokines and enhanced infiltration of innate immune cells, thus triggering the onset of colitis-associated carcinogenesis (CAC) in wild-type mice. Consequently, immunoproteasome-deficient animals (LMP2/MECL-1/LMP7–null mice) were almost completely resistant to CAC development. In patients with ulcerative colitis with high risk for CAC, immunoproteasome-induced protumorigenic mediators were upregulated. In melanoma tumors, the role of immunoproteasomes is relatively unknown. We found that high expression of immunoproteasomes in human melanoma was associated with better prognosis. Similarly, our data revealed that the immunoproteasome has antitumorigenic activity in a mouse model of melanoma. The antitumor immunity against melanoma was compromised in immunoproteasome-deficient mice because of the impaired activity of CD8+ CTLs, CD4+ Th1 cells, and antigen-presenting cells. These findings show that immunoproteasomes may exert opposing roles with either pro- or antitumoral properties in a context-dependent manner.Keywords
All Related Versions
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (FKZ 01Kl1702)
- ERACoSysMed2 - SysMed-COPD (FKZ 031L0140, 01EO1003 and 01EO1503 to)
- ERACoSysMed2 - SysMed-COPD (01EO1003 and 01EO1503 to)
- German Research Foundation (SFB/TR-84 TP C01, VI 562/10-1 to)
- German Research Foundation (VI 562/10-1 to)
- NIH (1R01HL141513, 1R01HL139641)
This publication has 33 references indexed in Scilit:
- Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in MicePLOS ONE, 2012
- Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell DifferentiationThe Journal of Immunology, 2012
- Mice completely lacking immunoproteasomes show major changes in antigen presentationNature Immunology, 2011
- Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I moleculesProceedings of the National Academy of Sciences, 2010
- Prevention of Experimental Colitis by a Selective Inhibitor of the ImmunoproteasomeThe Journal of Immunology, 2010
- Regulation of CD8 + T Cell Development by Thymus-Specific ProteasomesScience, 2007
- Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitisJournal of Clinical Investigation, 2006
- A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2004
- The proteasome: a proteolytic nanomachine of cell regulation and waste disposalBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2004
- 20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferencesFEBS Letters, 1996